loading
전일 마감가:
$3.565
열려 있는:
$3.56
하루 거래량:
710.46K
Relative Volume:
1.01
시가총액:
$209.55M
수익:
-
순이익/손실:
$-27.03M
주가수익비율:
-5.9821
EPS:
-0.56
순현금흐름:
$-23.97M
1주 성능:
-7.46%
1개월 성능:
+17.54%
6개월 성능:
-61.85%
1년 성능:
+75.39%
1일 변동 폭
Value
$3.325
$3.56
1주일 범위
Value
$3.325
$3.705
52주 변동 폭
Value
$1.43
$10.00

Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile

Name
명칭
Corvus Pharmaceuticals Inc
Name
전화
(650) 900-4520
Name
주소
863 MITTEN ROAD, BURLINGAME, CA
Name
직원
28
Name
트위터
Name
다음 수익 날짜
2025-03-25
Name
최신 SEC 제출 서류
Name
CRVS's Discussions on Twitter

CRVS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
CRVS
Corvus Pharmaceuticals Inc
3.35 209.55M 0 -27.03M -23.97M -0.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.03 129.44B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.52 61.42B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
615.11 38.44B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
269.81 33.29B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
241.75 26.95B 3.81B -644.79M -669.77M -6.24

Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-01-02 개시 H.C. Wainwright Buy
2023-08-18 개시 Oppenheimer Outperform
2021-12-01 재개 Jefferies Buy
2021-05-27 개시 Cantor Fitzgerald Overweight
2021-02-10 다운그레이드 Mizuho Buy → Neutral
2019-09-12 개시 Mizuho Buy
2019-05-29 개시 ROTH Capital Buy
2017-08-24 업그레이드 Credit Suisse Underperform → Neutral
2017-05-01 다운그레이드 Credit Suisse Neutral → Underperform
2016-04-18 개시 Credit Suisse Outperform
2016-04-18 개시 Guggenheim Buy
모두보기

Corvus Pharmaceuticals Inc 주식(CRVS)의 최신 뉴스

pulisher
May 02, 2025

Corvus Pharmaceuticals Inc (CRVS) deserves deeper analysis - uspostnews.com

May 02, 2025
pulisher
Apr 30, 2025

CRVS Stock: More Upside For Corvus Pharmaceuticals Inc (NASDAQ: CRVS)? - Marketing Sentinel

Apr 30, 2025
pulisher
Apr 30, 2025

Corvus Pharmaceuticals Inc [CRVS] Investment Appeal on the Rise - knoxdaily.com

Apr 30, 2025
pulisher
Apr 29, 2025

Gaining Ground: Corvus Pharmaceuticals Inc (CRVS) Closes Lower at 3.50, Down -3.58 - DWinneX

Apr 29, 2025
pulisher
Apr 29, 2025

Market Resilience: Corvus Pharmaceuticals Inc (CRVS) Finishes Strong at 3.38, Up 0.30 - DWinneX

Apr 29, 2025
pulisher
Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 25, 2025

An analyst sees good growth prospects for Corvus Pharmaceuticals Inc (CRVS) - Sete News

Apr 25, 2025
pulisher
Apr 24, 2025

Corvus Pharmaceuticals Inc (CRVS) deserves closer scrutiny - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

Upward Trajectory: Corvus Pharmaceuticals Inc (CRVS) Posts a Gaine, Closing at 3.52 - DWinneX

Apr 24, 2025
pulisher
Apr 24, 2025

Is Corvus Pharmaceuticals, Inc. (CRVS) the Best Multibagger Penny Stock to Buy According to Billionaires? - EMEA Tribune

Apr 24, 2025
pulisher
Apr 24, 2025

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025 - The Manila Times

Apr 24, 2025
pulisher
Apr 23, 2025

Corvus Pharmaceuticals Inc [CRVS] Investment Guide: What You Need to Know - knoxdaily.com

Apr 23, 2025
pulisher
Apr 23, 2025

Novel Atopic Dermatitis Treatment Shows Promise: Key Phase 1 Trial Results To Be Unveiled at Major Conference - Stock Titan

Apr 23, 2025
pulisher
Apr 21, 2025

Corvus Pharmaceuticals Inc (NASDAQ: CRVS) – Analysts’ Revisions Point To Positive Sentiment - Stocksregister

Apr 21, 2025
pulisher
Apr 10, 2025

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors - The Manila Times

Apr 10, 2025
pulisher
Apr 09, 2025

Corvus Pharmaceuticals expands board with new director By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 09, 2025

Corvus Pharmaceuticals Appoints Richard A. Van Den Broek To Board Of Directors - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Corvus Pharmaceuticals expands board with new director - Investing.com Australia

Apr 09, 2025
pulisher
Apr 09, 2025

Corvus Pharmaceuticals Appoints New Director to Board - TipRanks

Apr 09, 2025
pulisher
Apr 09, 2025

Strategic Win: Corvus Pharmaceuticals Lands Former Pharmacyclics Director with ITK Expertise - Stock Titan

Apr 09, 2025
pulisher
Apr 07, 2025

Corvus Pharmaceuticals’ Earnings Call: Progress Amid Challenges - MSN

Apr 07, 2025
pulisher
Mar 29, 2025

Research Analysts Issue Forecasts for CRVS FY2028 Earnings - The AM Reporter

Mar 29, 2025
pulisher
Mar 28, 2025

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call Transcript - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

Corvus Pharmaceuticals Stock: Now At Cruising Altitude (NASDAQ:CRVS) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

Corvus Pharmaceuticals: Now At Cruising Altitude (NASDAQ:CRVS) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 27, 2025

Corvus Pharmaceuticals at H.C. Wainwright Conference: Socolitinib’s Promising Trials By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 27, 2025

Institutions along with retail investors who hold considerable shares inCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) come under pressure; lose 24% of holdings value - simplywall.st

Mar 27, 2025
pulisher
Mar 27, 2025

Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger - Asianet Newsable

Mar 27, 2025
pulisher
Mar 26, 2025

Insider Buyers At Corvus Pharmaceuticals Sitting On US$1.3m Profit - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $15 From $14, Maintains Outperform Rating - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Mar 26, 2025
pulisher
Mar 26, 2025

Corvus Pharmaceuticals Inc (CRVS) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada

Mar 26, 2025
pulisher
Mar 25, 2025

Corvus Pharmaceuticals Reports 2024 Financial Results and Clinical Progress - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

Earnings call transcript: Corvus Pharmaceuticals Q4 2024 sees wider loss By Investing.com - Investing.com Canada

Mar 25, 2025
pulisher
Mar 25, 2025

Corvus: Q4 Earnings Snapshot - Greenwich Time

Mar 25, 2025
pulisher
Mar 25, 2025

Earnings call transcript: Corvus Pharmaceuticals Q4 2024 sees wider loss - Investing.com India

Mar 25, 2025
pulisher
Mar 25, 2025

Corvus Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 25, 2025
pulisher
Mar 25, 2025

CORVUS PHARMACEUTICALS Earnings Results: $CRVS Reports Quarterly Earnings - Nasdaq

Mar 25, 2025
pulisher
Mar 23, 2025

CORVUS PHARMACEUTICALS Earnings Preview: Recent $CRVS Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 23, 2025
pulisher
Mar 21, 2025

Corvus Pharmaceuticals Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView

Mar 21, 2025
pulisher
Mar 21, 2025

Brokerages Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) PT at $12.38 - Armenian Reporter

Mar 21, 2025
pulisher
Mar 20, 2025

Corvus Pharma Reports Positive Data From Phase 1/1b Study Of Soquelitinib In T Cell Lymphoma - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma - The Manila Times

Mar 20, 2025
pulisher
Mar 20, 2025

New Cancer Drug Achieves 39% Response Rate in T Cell Lymphoma Patients - Stock Titan

Mar 20, 2025

Corvus Pharmaceuticals Inc (CRVS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.42
price down icon 5.24%
$67.87
price down icon 6.49%
$32.11
price down icon 2.70%
$24.20
price down icon 13.63%
$94.74
price down icon 6.29%
biotechnology ONC
$241.75
price down icon 4.88%
자본화:     |  볼륨(24시간):